Sacituzumab Govitecan-hziy(Gilead / Immunomedics)은 Metastatic Urothelial Cancer 표적 ADC로, Metastatic Urothelial Cancer 영역에서 개발·상용화 중입니다. 작용기전: targeting antibody-drug conjugate (ADC), sacituzumab govitecan-hziy (Trodelvy), has shown efficacy in targeting this antigen. Phase 2에서 효능·안전성 신호를 검증 중입니다. 대표 임상 효능: ORR 34.3% (ClinicalTrials.gov NCT01631552). 차별점: novel antibody drug conjugate that has recently been approved by the Food and Drug Administration (FDA) in adult patients for.
Metastatic Urothelial Cancer
Metastatic Urothelial Cancer
Recruiting
ADC), sacituzumab govitecan-hziy (Trodelvy), has shown efficacy
govitecan-hziy (Trodelvy), has shown efficacy in
cleavable linker
humanized monoclonal antibody targeting trophoblast cell surface antigen 2, which is overexpressed in many so
novel antibody drug conjugate that has recently been approved by the Food and Drug Administration (FDA) in adult patients for
targeting antibody-drug conjugate (ADC), sacituzumab govitecan-hziy (Trodelvy), has shown efficacy in targeting this antigen
topoisomerase I inhibitor payload have recently emerged in the breast cancer (BC) treatment landscape
Trop2 expression
resistance mechanisms of SG along with key ongoing clinical trials, emphasizing its role in managing refractory mTNBC, especially in third-l
차트 로드 중…
임상시험이 많습니다. 임상시험 탭에서 Phase/Status 필터·검색을 사용하세요.
수집된 임상 필드(phase, status, endpoint 등) 기반 자동 요약입니다.
Sacituzumab Govitecan-hziy(Gilead / Immunomedics)은 Metastatic Urothelial Cancer 표적 ADC로, Metastatic Urothelial Cancer 영역에서 개발·상용화 중입니다. 작용기전: targeting antibody-drug conjugate (ADC), sacituzumab govitecan-hziy (Trodelvy), has shown efficacy in targeting this antigen. Phase 2에서 효능·안전성 신호를 검증 중입니다. 대표 임상 효능: ORR 34.3% (ClinicalTrials.gov NCT01631552). 차별점: novel antibody drug conjugate that has recently been approved by the Food and Drug Administration (FDA) in adult patients for.
Metastatic Urothelial Cancer
Metastatic Urothelial Cancer
Recruiting
ADC), sacituzumab govitecan-hziy (Trodelvy), has shown efficacy
govitecan-hziy (Trodelvy), has shown efficacy in
cleavable linker
humanized monoclonal antibody targeting trophoblast cell surface antigen 2, which is overexpressed in many so
novel antibody drug conjugate that has recently been approved by the Food and Drug Administration (FDA) in adult patients for
targeting antibody-drug conjugate (ADC), sacituzumab govitecan-hziy (Trodelvy), has shown efficacy in targeting this antigen
topoisomerase I inhibitor payload have recently emerged in the breast cancer (BC) treatment landscape
Trop2 expression
resistance mechanisms of SG along with key ongoing clinical trials, emphasizing its role in managing refractory mTNBC, especially in third-l
차트 로드 중…
임상시험이 많습니다. 임상시험 탭에서 Phase/Status 필터·검색을 사용하세요.
수집된 임상 필드(phase, status, endpoint 등) 기반 자동 요약입니다.